Jim Simons
MGX icon

Jim Simons’s Metagenomi Therapeutics MGX Stock Holding History

Jim Simons’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$883K Sell
742,400
-45,500
-6% -$60.9K ﹤0.01% 2370
2026
Q1 		$1.06M Buy
787,900
+159,500
+25% +$248K ﹤0.01% 2243
2025
Q4 		$1.02M Buy
628,400
+461,400
+276% +$999K ﹤0.01% 2272
2025
Q3 		$396K Buy
167,000
+48,000
+40% +$97.4K ﹤0.01% 2886
2025
Q2 		$176K Buy
119,000
+19,400
+19% +$30.4K ﹤0.01% 3195
2025
Q1 		$135K Sell
99,600
-54,200
-35% -$129K ﹤0.01% 3149
2024
Q4 		$555K Sell
153,800
-28,300
-16% -$68.3K ﹤0.01% 2794
2024
Q3 		$395K Buy
+182,100
New +$632K ﹤0.01% 2881

Other funds holding MGX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Catalio Capital Management
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
Peapod Lane Capital
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Bridgeway Capital Management
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Pura Vida Investments
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jim Simons's MGX Position: Q2 2026 in Review

Jim Simons reduced its Metagenomi Therapeutics (MGX) stake by 5.8% in Q2 2026, selling an estimated $60.9K and leaving 742,400 shares worth $883K. The position accounts for ﹤0.01% of the portfolio, ranked #2370.

Jim Simons first reported a position in MGX in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.06M in Q1 2026. 43 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

  • Jim Simons held 742,400 shares of Metagenomi Therapeutics worth $883K as of Q2 2026.
  • Jim Simons sold 45,500 Metagenomi Therapeutics shares in Q2 2026, an estimated $60.9K.
  • Metagenomi Therapeutics made up ﹤0.01% of Jim Simons's portfolio in Q2 2026, its #2370 holding.
  • Jim Simons first reported a position in Metagenomi Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Jim Simons's Metagenomi Therapeutics position peaked at $1.06M in Q1 2026.
  • 43 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.